# FDA WARNING_LETTER - ARG Laboratories, Inc. - September 20, 2023

Source: https://www.keypedia.com/records/warning_letter/arg-laboratories-inc/c1638d4c-61d5-4d7a-84cc-d99edf5b63c5

> FDA WARNING_LETTER for ARG Laboratories, Inc. on September 20, 2023. Product: Drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: WARNING_LETTER
- Company Name: ARG Laboratories, Inc.
- Inspection Date: 2023-09-20
- Product Type: Drugs
- Office Name: Office of Pharmaceutical Quality Operations Division I
- Summary: The FDA inspected ARG Laboratories, Inc. from September 11-20, 2023, identifying significant Current Good Manufacturing Practice (CGMP) violations, rendering their drug products adulterated. Additionally, "Golden Tiger Natural Pain Relieving Cream" and "Pain Wizard Natural Relief for Muscular & Arthritic Pain" were cited as unapproved new drugs and misbranded.

Key violations include:
1. **Inadequate Quality Unit (QU):** The QU failed to establish adequate procedures for supplier qualification, change control, OOS investigations, recalls, and complaint handling. Notably, products failing specifications were released. The firm's response was deemed inadequate for lacking a comprehensive CAPA plan.
2. **Insufficient Component Testing:** The firm failed to verify the identity of each component, including high-risk ingredients like propylene glycol and octocrylene, and did not validate supplier COAs. This raises concerns about hazardous impurities like DEG/EG. The response was inadequate, lacking detailed testing plans and a retrospective review.
3. **Lack of Process and Cleaning Validation:** The firm admitted to not conducting process or cleaning validation studies for non-dedicated equipment, nor validating their water system. The response was inadequate, lacking detail, risk assessment, or corrective actions for distributed products.
4. **Failure to Follow Stability Program:** The firm did not follow written stability procedures or provide documentation to support expiration dates. The response was inadequate, as it did not address the lack of

## Related Documents

- [483 - 2023-09-20](https://www.keypedia.com/records/483/arg-laboratories-inc/f18ffba7-1e09-420b-b1c8-5de2d8cd767d)

## Related Officers

- [Program Division Director](https://www.keypedia.com/people/monica-r-maxwell/e1b3373a-80b0-4023-9aea-b4ac7170c964)

Company: https://www.keypedia.com/companies/arg-laboratories-inc/49fb4cb7-04d3-453c-bb53-b91999553898

Office: https://www.keypedia.com/offices/office-of-pharmaceutical-quality-operations-division-i/798d6a62-d1f1-4f7c-8de3-465e277c13da